<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">$7.1 ...

CTOR

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Oncology shows LYMPHIR momentum driving institutional uptake and revenue ramp

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p xmlns=&quot;http://www.w3.org/1999/xhtml&quot; class=&quot;prntac&quot;&gt;&lt;i xmlns=&quot;http://www.w3.org/1999/xhtml&quot;&gt;$7.1 ...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Citius Oncology reported fiscal Q3 2026 results for LYMPHIR, highlighting accelerating institutional demand with vials ordered by 44 centers and 383 vials in July—the largest month to date. Management targets formulary inclusion at 100 priority institutions by year-end and nationwide commercial expansion, suggesting a meaningful revenue ramp into fiscal 2027 despite ongoing losses. The company also noted liquidity improvement from warrants and a loan tranche, supporting near-term commercialization efforts.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>LYMPHIR vials ordered 926 in Q3 ended 6/30/2026; 44 institutions.</li><li>July wholesaler orders: 383 vials; largest month to date.</li><li>Plan to reach 100 priority institutions by year-end; nationwide commercial coverage.</li><li>Nine months ended 6/30/2026 revenue: $7.1M; cash: $16.6M; warrants/loan funding.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Citius Oncology, Inc. (CTOR)</strong>: LYMPHIR momentum and adoption drive potential near-term revenue upside; institutional demand accelerating.</li><li><strong>Citius Pharmaceuticals, Inc. (CTXR)</strong>: Parent company; CTOR majority-owned; expansion supports CTSUS’ commercialization push.</li><li><strong>EVERSANA (N/A)</strong>: Exclusive commercialization partner; expanded field team to accelerate LYMPHIR rollout nationwide.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Earnings: Quarterly financials and business update tied to LYMPHIR commercialization and adoption metrics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>LYMPHIR vial orders accelerate: 31% sequential increase to 926 vials.</li><li>July wholesale orders translate to revenue as orders are fulfilled.</li><li>Commercial footprint expanded by 29 sales/medical staff; 8 MSLs with EVERSANA.</li><li>Liquidity gains: ~$9.7M from warrant exercises; $10M first tranche of term loan; cash 6/30/2026 at $16.6M.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Nine months ended June 30, 2026 revenue: $7.1 million; prior-year nine months: $0.</li><li>Three months ended June 30, 2026 revenue: $1.5 million; prior-year quarter: $0.</li><li>Cash and cash equivalents: $16.6 million as of June 30, 2026.</li><li>In July 2026, 383 institutional vials were ordered from wholesalers.</li><li>LYMPHIR prescribed/ordered by 44 institutions as of Aug 14, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>CTOR could re-rate on accelerating LYMPHIR revenue visibility within 6–12 months as institutional adoption expands.</p>
  </section>
</section>


<article>
  <header>
    <h2>Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update</h2>
  </header>

  <section id="opening-summary">
    <p><strong>$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR<sup>®</sup> launch progresses</strong>. Citius Oncology, Inc. (CTOR), an oncology-focused biopharmaceutical company and a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (CTXR), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update. The release highlights continued momentum behind LYMPHIR and growing institutional adoption in the U.S. market.</p>
    <p>CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Oncology, Inc. (CTOR) (NASDAQ: <a href="https://www.benzinga.com/quote/CTOR">CTOR</a>), an oncology-focused biopharmaceutical company and a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (CTXR) (NASDAQ: <a href="https://www.benzinga.com/quote/CTXR">CTXR</a>), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update.</p>
  </section>

  <section id="lymphhir-launch-demand">
    <h3>LYMPHIR Launch and Institutional Demand</h3>
    <p>“Institutional demand (LYMPHIR vials ordered by prescribing centers from wholesalers) is accelerating. Institutional vial orders grew 31% sequentially, from 708 in the quarter ended March 31, 2026 to 926 in the quarter ended June 30, 2026. In July, institutions ordered 383 vials from wholesalers, the largest order month to date, reflecting a 25% increase over the prior quarter's monthly average order. Currently, 44 institutions have prescribed and ordered LYMPHIR,” said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology.</p>
    <p>“We expect continued institutional demand to drive new wholesaler orders. The Company recognizes revenue when wholesaler orders are fulfilled. Consequently, net revenue for any period reflects actual wholesaler orders fulfilled. In July, we began to see growth in institutional demand translate into increased wholesale orders and associated revenue. The positive trajectory of formulary approvals, institutional adoption, and unit demand gives us confidence in a robust remainder of the fiscal year,” added Mazur.</p>
    <p>“We generated initial momentum with a lean internal team, maintaining healthy product margins and securing broad market access. In August, our full 29-person-strong commercial and medical affairs organizations expanded to nationwide coverage. The teams are now positioned to accelerate commercial execution and support broader adoption by leveraging the comprehensive, scalable infrastructure already established for LYMPHIR, including patient hub services, marketing and reimbursement support. Citius Oncology is now well positioned to broaden engagement with treatment centers, targeting formulary inclusion at 100 priority institutions by year-end and first-in-class support for health care providers. At the same time, we continue to advance LYMPHIR's longer-term value proposition through investigator-initiated studies exploring its potential in combination regimens beyond CTCL,” added Mazur.</p>
    <p>“Overall, the launch is moving in the right direction: more institutions are ordering LYMPHIR, vial demand is increasing, and our commercial footprint is expanding. We believe the underlying increasing demand trends provide a strong basis for the remainder of fiscal 2026,” concluded Mazur.</p>
  </section>

  <section id="business-highlights">
    <h3>Fiscal Third Quarter 2026 Business Highlights and Subsequent Developments</h3>
    <ul>
      <li>Secured prescriptions and orders from 44 institutions for LYMPHIR<sup>®</sup> (denileukin diftitox-cxdl), including academic oncology centers, leading National Comprehensive Cancer Network (NCCN) institutions, and community infusion centers;</li>
      <li>Increased the number of new ordering institutions by 80% in the quarter ended June 30, 2026, compared to the quarter ended March 31, 2026;</li>
      <li>Grew the number of vials ordered by institutions from wholesalers by 31% in the quarter ended June 30, 2026, compared to the quarter ended March 31, 2026, with <strong>383</strong> institutional vials ordered in July 2026, the largest vial order month to date;</li>
      <li>Secured near-universal payer coverage, with no reimbursement denials or prior authorization barriers reported to date;</li>
      <li>Expanded the commercial organization by 21 additional field-based professionals and added eight medical science liaisons, executed by the Company's exclusive commercialization partner, EVERSANA;</li>
      <li>Engaged U.S. and international CTCL key opinion leaders at the Sixth World Congress of Cutaneous Lymphomas in Montreal through scientific exchange and educational initiatives;</li>
      <li>Advanced two investigator-initiated Phase 1 studies of LYMPHIR in combination settings:
        <ul>
          <li>Phase 1 data for LYMPHIR with pembrolizumab in recurrent or refractory gynecologic cancers presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating:
            <ul>
              <li>20.5 months of median progression-free survival among 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21),</li>
              <li>Responses observed in patients previously treated with immune checkpoint inhibitors, including a 24% objective response rate (ORR) overall, and 33% ORR in patients with relapsed or refractory endometrial cancer; and,</li>
            </ul>
          </li>
          <li>Phase 1 data for LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) presented at 2026 ASTCT<sup>®</sup> &amp; CIBMTR<sup>®</sup> Tandem Meetings, demonstrating:
            <ul>
              <li>86% ORR, including 57% complete response (CR) and 29% partial response (PR),</li>
              <li>LYMPHIR was well-tolerated with no dose-limiting toxicities observed; and,</li>
            </ul>
          </li>
        </ul>
      </li>
      <li>Appointed Jonathan Peri, Ph.D., J.D., as an independent director on August 10, 2026, bringing three decades of leadership experience across law, financial services and corporate governance.</li>
    </ul>
  </section>

  <section id="financial-highlights">
    <h3>Fiscal Third Quarter 2026 Financial Highlights and Subsequent Developments</h3>
    <ul>
      <li>Cash and cash equivalents of ...</li>
    </ul>
  </section>
</article>

Citius Oncology reported fiscal Q3 2026 results for LYMPHIR, highlighting accelerating institutional demand with vials ordered by 44 centers and 383 vials in July—the largest month to date. Management targets formulary inclusion at 100 priority institutions by year-end and nationwide commercial expansion, suggesting a meaningful revenue ramp into fiscal 2027 despite ongoing losses. The company also noted liquidity improvement from warrants and a loan tranche, supporting near-term commercialization efforts.

News insight

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

AI summary

Sentiment rationale

Key facts

Earnings